The current standard of care for non-metastatic HER2 + BC includes chemotherapy in combination with HER2-targeting agents, based on the results of adjuvant pivotal trials showing that the addition of trastuzumab for one year to polychemotherapy leads to a significant reduction in the risk of relapse and death2–5. Here, ERBB2 is linked to breast cancer.